GLUCOSAMINE supplements accelerate dementia progression and increase mortality risk in older adults, according to recent research. Investigators discovered that excessive brain hyperglycosylation acts as an active metabolic driver of Alzheimer’s disease pathophysiology. Analyzing postmortem human cortical tissue and mouse models revealed widespread accumulation of complex N-glycans across vulnerable brain regions, including the cortex and hippocampus. In human gray matter, this abnormal glycosylation intensified across progressive Braak stages, depleting critical biosynthetic precursors like glucosamine-6-phosphate. Glycoproteomic profiling showed that this pathway primarily alters pre-existing neuronal membrane proteins essential for synaptic communication rather than generating novel glycoproteins.
Metabolic flux analyses utilizing stable carbon isotope tracing confirmed that elevated de novo glycan synthesis, rather than impaired lysosomal recycling, drives the disease state. Enzymes within the hexosamine biosynthetic pathway showed significant transcriptomic upregulation in both human patients and transgenic mice. Experimental genetic knockdown of phosphoglucomutase 3 or chemical inhibition of the oligosaccharyltransferase complex reduced aberrant glycan levels and restored social recognition memory in preclinical models. These therapeutic gains occurred without reducing beta-amyloid plaques, tau pathology, or reactive astrogliosis, highlighting glycan metabolism as an independent therapeutic target.
Because oral glucosamine readily crosses the blood-brain barrier to fuel the hexosamine pathway, researchers tested its direct impact on neurodegeneration. In transgenic Alzheimer’s disease mice, daily oral glucosamine exacerbated cognitive deficits and elevated cerebral N-glycan burdens. Expanding the investigation into real-world human data, researchers examined electronic health records from more than 24,000 patients with dementia and 41,000 individuals with mild cognitive impairment. Documented glucosamine use was associated with a 25% higher mortality risk among dementia patients, alongside a 25% increased rate of progression from mild cognitive impairment to full dementia. Conversely, cognitively intact wild-type mice exhibited metabolic resilience to glucosamine, showing neither elevated glycans nor memory impairment. These findings indicate that glucosamine poses unique risks in the context of existing neurodegeneration, underscoring the need for clinicians to monitor over-the-counter supplement use.
Reference
Hawkinson TR et al. Hyperglycosylation is a metabolic driver of Alzheimer’s disease. Nat Metab. 2026;8:1410-1425.
Sebastian Kaulitzki on adobe stock
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
